Lanzoprazole promotes gastric carcinogenesis in rats with duodenogastric reflux

Gastric Cancer. 2004;7(1):31-5. doi: 10.1007/s10120-003-0264-1.

Abstract

Background: Duodenogastric reflux is known to cause an increased frequency of cancer in the glandular portion of the stomach in rats. Furthermore, it is debated whether inhibition of gastric acid secretion may promote gastric carcinogenesis. In the present study we examined the combined effect of gastroduodenal reflux and acid inhibition with respect to the development of gastric carcinoma in the rat.

Methods: Following the construction of a gastrojejunostomy in male Wistar rats, half of them were given the proton pump inhibitor lanzoprazole for 1 year. The rats were then killed and the pH in the stomach and gastrin in blood were measured. The stomach was examined macroscopically as well as histologically.

Results: Gastrin levels at autopsy were significantly increased in treated rats compared to the control group, confirming an effect of lanzoprazole on gastric acid secretion. Body weight was significantly reduced in the treated rats. Thirty of 79 rats developed gastric cancer, and they were all adenocarcinomas of the Lauren intestinal type. Gastric cancers occurred significantly more often in lanzoprazole-treated rats (50%) compared with controls (27%).

Conclusion: Lanzoprazole given orally enhances the carcinogenic effect of duodenogastric reflux in rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adenocarcinoma / etiology*
  • Adenocarcinoma / physiopathology*
  • Adenocarcinoma / veterinary
  • Administration, Oral
  • Animals
  • Duodenogastric Reflux / complications*
  • Duodenogastric Reflux / drug therapy*
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / adverse effects*
  • Gastrins / analysis
  • Lansoprazole
  • Male
  • Omeprazole / administration & dosage
  • Omeprazole / adverse effects*
  • Omeprazole / analogs & derivatives*
  • Rats
  • Rats, Wistar
  • Stomach Neoplasms / etiology*
  • Stomach Neoplasms / physiopathology*
  • Stomach Neoplasms / veterinary

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Enzyme Inhibitors
  • Gastrins
  • Lansoprazole
  • Omeprazole